Proteomic analysis reveals upregulation of RKIP in S-180 implanted BALB/C mouse after treatment with ascorbic acid

Journal of Cellular Biochemistry

Volumn 106, Issue 6, 2009, Pages 1136-1145

  Park, Seyeon ^a   Eun, Sook Ahn ^a   Lee, Sukchan ^b   Jung, Manyong ^b   Jin, Hee Park ^b   Sang, Yeop Yi ^c   Yeom, Chang Hwan ^d  

^a Dongduk Women's University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Kwandong University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

Ascorbic acid; Proteomics; Raf kinase inhibitory protein

Indexed keywords

ASCORBIC ACID; LIPOCORTIN 5; MESSENGER RNA; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; LIVER METASTASIS; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SARCOMA 180; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ANIMALS; ANNEXIN A5; ANTIOXIDANTS; ASCORBIC ACID; CELL LINE, TUMOR; HUMANS; LIVER; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEOME; SARCOMA 180; SURVIVAL RATE;

MUS;

EID: 66149098122     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22097     Document Type: Article

References (37)

1. Bernier I, Tresca JP, Jolles P. 1986. Ligand-binding studies with a 23 kDa protein purified from bovine brain cytosol. Biochim Biophys Acta 871:19-23.
2. Bram S, Froussard P, Guichard M, Jasmin C, Augery Y, Sinoussi-Barre F, Wray W. 1980. Ascorbic acid preferential toxicity for malignant melanoma cells. Nature 284:629-631.
3. Bruchelt G, Baader L, Reith AG, Holger NL, Gebhardt S, Niethammer D. 1993. Rationale for the use of ascorbic acid in neuroblastoma therapy. Human Neuroblastoma. Newark: Harwood Academic Publishers. pp 34-40.
4. Bruun AW, Svendsen I, Sorensen SO, Kielland-Brandt MC, Winther JR. 1998. A high-affinity inhibitor of yeast carboxypeptidase Y is encoded by TFS1 and shows homology to a family of lipid binding proteins. Biochemistry 37:3351-3357.
5. Chang L, Karin M. 2001. Mammalian MAP kinase signalling cascades. Nature 410:37-40.
6. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, Keller ET, Sedivy JM, Yeung KC. 2004. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279:17515-17523.
7. De Laurenzi V, Melino G, Savini I, Annicchiarico-Petruzzelli M, Finazzi-Agro A, Avigliano L. 1995. Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines. Eur J Cancer 31A:463-466.
8. Fidler IJ. 1999. Critical determinants of cancer metastasis: Rationale for therapy. Cancer Chemother Pharmacol 43:S3-S10.
9. Frayne J, Ingram C, Love S, Hall H. 1999. Localisation of phosphatidylethanolamine-binding protein in the brain and other tissues of the rat. Cell Tissue Res 298:415-423.
10. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. 2003. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95:878-889.
11. Fujinaga S, Sakagami H, Kuribayashi N, Takahashi H, Amano Y, Sakagami T, Takeda M. 1994. Possible role of hydrogen peroxide in apoptosis induction by ascorbic acid in human myelogenous leukemic cell lines. Showa Univ Med Sci 6:135-144.
12. Gruber HE, Tewfik HH, Tewfik FA. 1980. Cytoarchitecture of Ehrlich ascites carcinoma implanted in the hind limb of ascorbic acid-supplemented mice. Eur J Cancer 16:441-448.
13. Keller ET, Fu Z, Brennan M. 2004. The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol 68:1049-1053.
14. Keller ET, Fu Z, Brennan M. 2005. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 94:273-278.
15. Kohn EC. 1993. Development and prevention of metastasis. Anticancer Res 13:2553-2559.
16. Kondoh K, Torii S, Nishida E. 2005. Control of MAP kinase signaling to the nucleus. Chromosoma 114:86-91.
17. Kroslak T, Koch T, Kahl E, Hollt V. 2001. Human phosphatidylethanolaminebinding protein facilitates heterotrimeric G protein-dependent signaling. J Biol Chem 276:39772-39778.
18. Krupnick JG, Benovic JL. 1998. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 38:289-319.
19. Lorenz K, Lohse MJ, Quitterer U. 2003. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426:574-579.
20. Markoff A, Bogdanova N, Knop M, Rüffer C, Kenis H, Lux P, Reutelingsperger C, Todorov V, Dworniczak B, Horst J, Gerke V. 2007. Annexin A5 interacts with polycystin-1 and interferes with the polycystin-1 stimulated recruitment of E-cadherin into adherens junctions. J Mol Biol 369:954-966.
21. Meadows GG, Pierson HF, Abdallah RM. 1991. Ascorbate in the treatment of experimental transplanted melanoma. Am J Clin Nutr 54:1284S-1291S.
22. Mignatti P, Rifkin DB. 1993. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195.
23. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. 2004. Vitamin C pharmacokinetics: Implications for oral and intravenous use. Ann Intern Med 140:533-537.
24. Park CH. 1985. Biological nature of the effect of ascorbic acids on the growth of human leukemic cells. Cancer Res 45:3969-3973.
25. Park CH, Kimler BF, Bodensteiner D, Lynch SR, Hassanein RS. 1992. In vitro growth modulation by L-ascorbic acid of colony-forming cells from bone marrow of patients with myelodysplastic syndromes. Cancer Res 52:4458-4466.
26. Park S, Han SS, Park CH, Hahm ER, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Kimler BF, Kim K, Lee JH. 2004. L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxidemediated mechanisms. Int J Biochem Cell Biol 36:2180-2195.
27. Park S, Yeung ML, Beach S, Shields JM, Yeung KC. 2005. RKIP down-regulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24:3535-3540.
28. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. 2001. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22:153-183.
29. Pnueli L, Gutfinger T, Hareven D, Ben-Nairn O, Ron N, Adir N, Lifschitz E. 2001. Tomato SP-interacting proteins define a conserved signaling system that regulates shoot architecture and flowering. Plant Cell 13:2687-2702.
30. Rath M, Pauling L. 1992. Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. Orthomol Med 7:17-23.
31. Roomi MW, Roomi NW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. 2005. Modulation of N-methyl-N-nitrosourea induced mammary tumors in Sprague-Dawley rats by combination of lysine, proline, arginine, ascorbic acid and green tea extract. Breast Cancer Res 7:R291-R295.
32. Taper HS, Jamison JM, Gilloteaux J, Summers JL, Calderon PB. 2004. Inhibition of the development of metastases by dietary vitamin C:K3 combination. Life Sci 75:955-967.
33. Trakul N, Rosner MR. 2005. Modulation of the MAP kinase signaling cascade by Raf kinase inhibitory protein. Cell Res 15:19-23.
34. Wybieralska E, Koza M, Sroka J, Czyz J, Madeja Z. 2008. Ascorbic acid inhibits the migration of Walker 256 carcinosarcoma cells. Cell Mol Biol Lett 13:103-111.
35. Yang SH, Kim JS, Oh TJ, Kim MS, Lee SW, Woo SK, Cho SH, Chio YH, Kim YH, Rha SW, Chung HC, An SW. 2003. Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int J Oncol 22:741-750.
36. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. 1999. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401:173-177.
37. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. 2001. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 21:7207-7217.